This study corroborates preclinical evidence that regardless of BRCA1 status, PARP inhibition radiosensitizes cancer cells including breast cancer cells across two distinct forms of radiotherapy, probably through unresolved DNA damage13–15,18−21,31. This evidence concerns the gene PARP1 and breast carcinoma.